Berkshire requires a 25–50% discount to intrinsic value before buying.
Buffett Quality Checklist
✓ROE >15% consistently (≥7 of last 10 years)
✓Free cash flow positive (≥8 of last 10 years)
✓Conservative leverage — Debt/Equity below 1
✓Revenue growing at CAGR >5%
✗EPS growing at CAGR >5%
10-Year Financial History — SEC EDGAR 10-K Filings
Year▲
Revenue▲
Net Income▲
FCF▲
Owner Earnings▲
ROE▲
Net Margin▲
LT Debt▲
Cash▲
2016
$25.6B
$6.0B
—
$5.9B
128.4%
23.2%
—
$5.1B
2017
$28.2B
$5.3B
$9.4B
$5.2B
104.2%
18.8%
—
$9.3B
2018
$32.8B
$5.7B
$12.8B
$5.5B
—
17.4%
—
$7.3B
2019
$33.3B
$7.9B
$12.8B
$7.8B
—
23.7%
$67.2B
$39.9B
2020
$45.8B
$4.6B
$16.8B
$4.5B
35.3%
10.1%
$84.9B
$8.4B
2021
$56.2B
$11.5B
$22.0B
$11.6B
74.9%
20.5%
$76.0B
$9.7B
2022
$58.1B
$11.8B
$24.2B
$11.9B
68.6%
20.4%
$63.1B
$9.2B
2023
$54.3B
$4.9B
$22.1B
$4.8B
46.9%
9.0%
$59.2B
$12.8B
2024
$56.3B
$4.3B
$17.8B
$4.1B
128.7%
7.6%
$66.8B
$5.5B
2025
$61.2B
$4.2B
$17.8B
$3.8B
—
6.9%
$64.5B
$5.2B
Warren & Charlie
Buffett / Munger — quality, moat & valuation
AbbVie Inc. (ABBV) — Investment Memo
🐂 The Bull Case (Warren's voice)
The Cash Engine: While the income statement is a mess of accounting noise, the real money—Free Cash Flow—is formidable at $17.8B. That is the only number that pays dividends and buys companies.
The "Replacement" Cycle: The moat isn't a wall; it's a relay race. They successfully transitioned the Humira cliff toward Skyrizi and Rinvoq. If they can continue to identify undervalued biotech assets and integrate them efficiently, they are effectively a compounding machine funded by their own cash flow.
Pricing Power: In the institutional healthcare market, AbbVie doesn't "compete" on price; they dictate it until the patent expires. This allows for extraordinary margins on new launches.
Attractive Entry: This becomes a Berkshire-style "fat pitch" if the market overreacts to a single pipeline failure or a regulatory hiccup, pushing the price deep into the $140–$160 range.
🐻 The Bear Case (Charlie inverts)
“Show me where I’ll die and I won’t go there.”
The "M&A Treadmill" Failure: The business is currently a parasite that must consume smaller biotech firms (Cerevel, ImmunoGen) just to maintain a flat line. If the cost of acquisition rises or the success rate of these "plugs" drops, the revenue decay becomes terminal.
The Regulatory Guillotine: The Inflation Reduction Act (IRA) and Medicare price negotiations aren't "risks"—they are structural shifts. If the government caps the pricing of the next generation of blockbusters, the mathematical premise of the "replacement cycle" collapses.
The Debt Jenga: With a capital-intensive model and a history of funding M&A with debt, a prolonged period of high interest rates combined with a revenue miss creates a liquidity trap.
Most Likely Death: The "Pipeline Gap." The most probable failure is a 2–3 year window where old patents expire faster than new acquisitions reach commercial scale (Timeframe: 2026–2029).
💰 Valuation & Margin of Safety
Reacting to the DCF estimate of $219.06:
Intrinsic value estimate: $219.06
25% margin of safety entry: $164.30(Conservative/Institutional)
50% margin of safety entry: $109.53(Buffett's ideal/Deep Value)
Current Status: Fairly valued to slightly expensive. At current market levels, we are paying for the "hope" that the M&A strategy works, without a sufficient cushion for the regulatory cliff.
Verdict: WATCH
The divergence between $17.8B FCF and $4.2B Net Income suggests a business in structural transition. While the cash flow is impressive, the reliance on a "shopping spree" to replace lost patents is not a durable moat. We wait for a price closer to $160 before committing capital.
Other Analyst Views· Lynch · Damodaran
Research Notes· Money Model · Moat · Financials · Management
Data sourced from SEC EDGAR XBRL filings (10-K only). For educational purposes — not investment advice.